Literature DB >> 11154114

Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII--an immunochemical and homology modeling approach.

F Citarella1, H te Velthuis, M Helmer-Citterich, C E Hack.   

Abstract

Monoclonal antibodies directed against functional sites of proteins provide useful tools for structure-function studies. Here we describe a mAb, KOK5, directed against the heavy chain region of human coagulation factor XII (FXII), which inhibits kaolin-induced clotting activity by preventing the binding of FXII to kaolin. Furthermore, mAb KOK5 enhances FXII susceptibility for cleavage by kallikrein and supports FXII autoactivation. Hence, mAb KOK5 likely is directed against the binding site of FXII for negatively charged surfaces. Screening of two phage-displayed random peptide libraries with mAb KOK5 selected phages that could be grouped on the basis of two amino acid consensus sequences: A) FXFQTPXW and B) HQ/LCTHR/KKC. Sequence A contains two motifs: one shares homology with FXII amino acid residues 30-33 (FPFQ), the second one with residues 57-60 (TPNF); both amino acid stretches belonging to the fibronectin type II domain of FXII. Sequence B also reveals homology with part of the fibronectin type II domain, i.e. the stretch 40-47 (HKCTHKGR). A three-dimensional model of FXII residues 28-65, obtained by homology modeling, indicated that the three amino acid stretches 30-33, 40-47 and 57-60 are close to each other and accessible for the solvent, i.e. in a form available for interaction with the monoclonal antibody, suggesting that mAb KOK5 recognizes a discontinuous epitope on the fibronectin type III domain of FXII. Peptides corresponding to FXII sequences 29-37 (FXII29-37) or 39-47 (FXII39-47), were synthesized and tested for the capability to inhibit FXII binding to negatively charged surfaces. Peptide FXII39-47 inhibited the binding of labeled FXII to kaolin and effectively prevented both dextran sulfate- and kaolin-induced activation of the contact system in plasma. Hence, we suggest that the fibronectin type II domain of FXII, in particular residues 39 to 47, contribute to the binding site of FXII for negatively charged surfaces.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11154114

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

1.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 2.  Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?

Authors:  Becky Woodruff; Bruce Sullenger; Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

3.  A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation.

Authors:  Zonne L M Hofman; Chantal C Clark; Wariya Sanrattana; Aziz Nosairi; Naomi M J Parr; Minka Živkovic; Karoline Krause; Niklas A Mahnke; Jörg Scheffel; C Erik Hack; Marcus Maurer; Steven de Maat; Coen Maas
Journal:  J Biol Chem       Date:  2019-11-26       Impact factor: 5.157

4.  Determinants of the thrombogenic potential of multiwalled carbon nanotubes.

Authors:  Andrew R Burke; Ravi N Singh; David L Carroll; John D Owen; Nancy D Kock; Ralph D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Biomaterials       Date:  2011-06-12       Impact factor: 12.479

5.  A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding.

Authors:  Boran Altincicek; Aya Shibamiya; Heidi Trusheim; Eleni Tzima; Michael Niepmann; Dietmar Linder; Klaus T Preissner; Sandip M Kanse
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

Review 6.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

Review 7.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

Review 8.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

9.  The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.

Authors:  D X Beringer; L M J Kroon-Batenburg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-26

10.  A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.

Authors:  Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Bassem M Mohammed; Qiufang Cheng; S Kent Dickeson; Suman Kundu; Ingrid M Verhamme; Andras Gruber; Keith McCrae; David Gailani
Journal:  Blood       Date:  2018-12-27       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.